See analyst estimates and all valuation multiples for Chemicals
| Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| $237B | 7.1x | 18.2x | |
| $102B | 4.4x | 22.3x | |
| $82.1B | 5.2x | 22.3x | |
| $75.7B | 6.3x | 15.0x | |
| $65.5B | 0.9x | 7.4x | |
| $50.2B | 2.8x | 7.4x | |
| $49.9B | 23.3x | 478.0x | |
| $48.5B | 3.4x | 17.5x | |
| $44.8B | 1.2x | 8.7x | |
| $42.3B | 1.6x | 7.6x | |
| $37.8B | 1.4x | 8.3x | |
| $36.8B | 0.9x | 7.5x | |
| $34.3B | 2.7x | 10.7x | |
| $34.0B | 7.6x | 20.5x | |
| $33.2B | 1.0x | 9.2x | |
| $31.5B | 2.2x | 12.6x | |
| $31.2B | 2.0x | 10.9x | |
| $29.3B | 0.8x | 7.5x | |
| $28.8B | 2.6x | 13.3x | |
| $26.9B | 0.8x | 6.0x | |
| $25.5B | 6.4x | 35.5x | |
| $24.2B | 2.1x | 12.8x | |
| $22.7B | 3.8x | 9.6x | |
| $20.8B | 3.7x | 10.8x | |
| $19.8B | 2.2x | 9.8x | |
| $18.4B | 3.2x | 15.5x | |
| $18.2B | 0.5x | 2.3x | |
| $18.2B | 1.8x | 8.2x | |
| $17.9B | 4.0x | 15.3x | |
| $16.8B | 6.8x | 23.4x | |
| $16.8B | 2.3x | 14.7x | |
| $16.5B | 2.7x | 7.0x | |
| $16.0B | 1.3x | 9.5x | |
| $15.7B | 3.1x | 11.1x | |
| $15.6B | 1.0x | 12.8x | |
| $14.0B | 0.8x | 6.0x | |
| $14.0B | 1.5x | 7.9x | |
| $13.1B | 0.9x | 5.8x | |
| $12.2B | 1.0x | 6.0x | |
| $11.4B | 2.5x | 7.7x | |
| $11.1B | 2.2x | 10.3x | |
| $10.2B | 1.5x | 6.0x | |
| $9.8B | 4.5x | 10.5x | |
| $9.5B | 0.5x | 5.8x | |
| $9.4B | 1.7x | 14.1x | |
| $9.3B | 1.3x | 6.0x | |
| $9.3B | 3.1x | 8.5x | |
| $8.6B | 2.0x | 9.6x | |
| $8.4B | 0.8x | 5.0x | |
| $7.8B | 0.6x | 3.0x | |
| $6.5B | 3.0x | 9.1x | |
| $6.5B | 6.8x | 25.2x | |
| $6.2B | 2.4x | 4650.9x | |
| $5.9B | 1.2x | 10.2x | |
| $5.7B | 1.4x | 9.4x | |
| $5.4B | 1.0x | 4.7x | |
| $5.4B | 1.1x | 6.6x | |
| $5.3B | 0.7x | 7.8x | |
| $5.3B | 0.6x | 6.9x | |
| $5.0B | 2.7x | 10.7x | |
| $4.7B | 0.4x | 14.4x | |
| $4.5B | 1.7x | 13.3x | |
| $4.4B | 5.8x | 20.1x | |
| $4.3B | 0.7x | 5.1x | |
| $4.2B | 10.3x | 32.7x | |
| $4.2B | n/a | n/a | |
| $3.7B | 1.1x | 5.7x | |
| $3.6B | 13.4x | 51.0x | |
| $3.6B | 1.6x | 7.9x | |
| $3.5B | 0.9x | 16.0x | |
| $3.4B | n/a | n/a | |
| $3.3B | 5.4x | 30.6x | |
| $2.9B | 0.8x | 111.6x | |
| $2.6B | 0.6x | 3.9x | |
| $2.3B | n/a | n/a | |
| $2.2B | 2.4x | 12.4x | |
| $2.1B | 0.7x | 5.3x | |
| $2.0B | 2.7x | 10.6x | |
| $1.9B | 0.7x | 5.8x | |
| $1.8B | 1.5x | 11.6x | |
| $1.7B | 0.2x | 5.5x | |
| $1.6B | 6.5x | 20.0x | |
| $1.4B | 1.4x | 8.3x | |
| $1.4B | 2.2x | 11.5x | |
| $1.3B | n/a | n/a | |
| $1.3B | 2.5x | n/a | |
| $1.3B | 1.8x | 7.7x | |
| $1.3B | 1.3x | 12.4x | |
| $996M | 0.6x | 6.0x | |
| $878M | 0.5x | 16.5x | |
| $851M | 2.0x | 29.6x | |
| $788M | n/a | n/a | |
| $718M | n/a | n/a | |
| $622M | 0.2x | 49.0x | |
| $603M | 0.5x | 4.2x | |
| $583M | 1.3x | 6.3x | |
| $580M | 1.0x | 7.4x | |
| $571M | n/a | n/a | |
| $554M | 1.5x | 10.1x | |
| $482M | 0.9x | 5.8x | |
| $452M | 1.8x | 11.9x | |
| $442M | 0.4x | 4.9x | |
| $429M | 8.9x | 28.7x | |
| $420M | 5.9x | -11.1x | |
| $407M | 0.6x | 5.7x | |
| $381M | 0.7x | 5.3x | |
| $346M | 1.6x | 8.8x | |
| $335M | 0.2x | 3.2x | |
| $322M | n/a | n/a | |
| $307M | 0.6x | 2.0x | |
| $298M | 8.2x | -8.6x | |
| $284M | n/a | n/a | |
| $283M | 0.5x | 6.2x | |
| $271M | n/a | n/a | |
| $234M | n/a | n/a | |
| $232M | n/a | n/a | |
| $183M | n/a | n/a | |
| $181M | 0.4x | 4.7x | |
| $171M | 294.7x | -334.1x | |
| $152M | 0.7x | 4.0x | |
| $142M | 9.7x | -5.0x | |
| $133M | 1.2x | 6.4x | |
| $131M | n/a | n/a | |
| $114M | 5.7x | 17.2x | |
| $109M | n/a | n/a | |
| $101M | n/a | n/a | |
| $95.3M | n/a | n/a | |
| $91.4M | 38.9x | -2.7x | |
| $86.5M | n/a | n/a | |
| $76.1M | 471.3x | -13.1x | |
| $71.4M | 0.6x | 9.5x | |
| $67.2M | 0.7x | 3.8x | |
| $61.0M | n/a | n/a | |
| $48.2M | 0.6x | 4.8x | |
| $45.4M | 0.8x | 21.7x | |
| $42.8M | 2.5x | 15.8x | |
| $42.7M | n/a | n/a | |
| $41.9M | 1.8x | -2.3x | |
| $35.0M | 0.6x | -55.5x | |
| $34.5M | 8.8x | -5.2x | |
| $33.2M | 1.6x | 29.1x | |
| $32.3M | n/a | n/a | |
| $31.7M | 0.4x | 8.4x | |
| $27.6M | 2.1x | 37.0x | |
| $25.9M | n/a | n/a | |
| $25.4M | n/a | n/a | |
| $24.9M | n/a | n/a | |
| $20.8M | 43.8x | -1.7x | |
| $20.6M | 2.0x | -10.0x | |
| $20.6M | n/a | n/a | |
| $19.7M | n/a | n/a | |
| $17.0M | n/a | n/a | |
| $16.0M | n/a | n/a | |
| $14.6M | n/a | n/a | |
| $14.6M | n/a | n/a | |
| $12.9M | 2.1x | 3798.4x | |
| $12.5M | 1.3x | -4.1x | |
| $11.9M | n/a | n/a | |
| $11.5M | n/a | n/a | |
| $7.6M | n/a | n/a | |
| $6.3M | n/a | n/a | |
| $6.1M | n/a | n/a | |
| $5.8M | 18.4x | -8.8x | |
| $5.7M | n/a | n/a | |
| $5.5M | n/a | n/a | |
| $5.4M | n/a | n/a | |
| $3.8M | n/a | n/a | |
| $3.6M | n/a | n/a | |
| $3.1M | n/a | n/a | |
| $2.8M | n/a | n/a | |
| $1.5M | n/a | n/a | |
| $1.5M | n/a | n/a | |
| $1.2M | n/a | n/a | |
| $1.1M | n/a | n/a | |
| $0.9M | n/a | n/a | |
| $0.7M | n/a | n/a | |
| $0.1M | n/a | n/a | |
| -$1.2M | -9.6x | 0.3x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Chemicals